GSK issued the following statement: “GSK plc today confirmed it has reached a confidential settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court. GSK does not admit any liability in this settlement. The case will now be dismissed. Since 2019, following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK says GSK3943104 did not meet Phase 2 study’s primary efficacy objective
- GSK presents full results from SWIFT-1 and SWIFT-2 Phase 3 trials
- GSK Reports Key Management Share Award
- GSK announces Phase III trial of Nucala met primary endpoint
- European Commission approves expanded age indication for GSK’s Arexvy